Predictive value of ¹⁸F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation

References

• Canellos GP. CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol 1997; 15(5):1713–1716.
   PubMed Web of Science ®Google Scholar
• Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998; 25(4): 483–491.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lym-phoma. N Engl J Med 1993; 329(14): 987–994.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11(5): 931–936.
   PubMed Web of Science ®Google Scholar
• Gordon BG, Warkentin PI, Weisenburger DD et al. Bone marrowtransplantation for peripheral T-cell lymphoma in children and adolescents. Blood 1992,80(11): 2938–2942.
   PubMed Web of Science ®Google Scholar
• Becherer A, Mitterbauer M, Jaeger U et al. Positron emission tomography with [18F]2-fouoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16(2): 260–267.
   PubMed Web of Science ®Google Scholar
• Cremerius U, Fabry U, Wildberger JE et al. Pre-transplant positronemission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30(2): 103–111.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplanta-tion. Blood 2003; 102(1): 53–59.
   PubMed Web of Science ®Google Scholar
• Filmont JE, Czernin J, Yap C et al. Value of F-18 fluorodeox-yglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124(2): 608–613.
   PubMed Web of Science ®Google Scholar
• Schot B, van Imhoff G, Pruim J et al. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosen-sitive relapsed lymphoma. Br J Haematol 2003,123(2): 282–287.
   PubMed Web of Science ®Google Scholar
• Schot BW, Pruim J, van Imhoff GW. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006; 91(4): 490–495.
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Elstrom R. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38(3): 211–216.
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Izutsu K, Takahashi M et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may over-come the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol 2008; 83(6): 477–481.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Canevari C, Assanlli A et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008; 49(4): 727–733.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Hustinx R, Beguin Y et al. Evaluation of therapy for lymphoma. Semin Nud Med 2005; 35(3): 186–196.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16(9): 1514–1523.
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lym-phoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106(4): 1376–1381.
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31(1): 22–28.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeox-yglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19(2): 414–419.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16(9): 1514–1523.
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lym-phoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31(1): 22–28.
   PubMed Web of Science ®Google Scholar
• Filmont JE, Gisselbrecht C, Cuenca X et al. The impact of pre- andpost-transplantation positron emission tomography using 18-fluor-odeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110(6): 1361–1369.
   PubMed Web of Science ®Google Scholar